Elsevier

Journal of Hepatology

Volume 22, Issue 1, January 1995, Pages 22-26
Journal of Hepatology

Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: effect of α-interferon therapy

https://doi.org/10.1016/0168-8278(95)80255-XGet rights and content

Abstract

Background/Aims: It has been suggested that increases in serum hyaluronan levels might be a marker of fibrosis in chronic viral hepatitis C. Patients receiving α-interferon therapy are an excellent model to determine the relationship between serum hyaluronan and liver fibrosis, since results suggest that α-interferon could reduce liver fibrosis.

Methods: We studied the relationship between serum hyaluronan and histopathological indices of liver fibrosis, inflammation and necrosis, before and after α-interferon therapy (3 MU, three times weekly for 6 months), and the effect of treatment on serum hyaluronan and on histological liver fibrosis, in 52 patients. Hyaluronan levels were measured using a radiometric assay and the liver histopathological indices were scored according to the Knodell system.

Results: The serum hyaluronan level correlated with the extent of liver fibrosis both before and after α-interferon therapy (p<0.0001), but not with the histopathological indices of liver inflammation or necrosis. Parallel changes in serum hyaluronan and liver fibrosis occurred: serum hyaluronan levels feel significantly in patients in whom fibrosis improved (p<0.01, n=11), increased significantly in patients in whom fibrosis worsened (p<0.05, n=10), and did not change significantly in patients in whom fibrosis was unmodified (n=31). Furthermore, fibrosis improved only when the antiviral effect of α-interferon was reflected by persistent normalization of serum alanine amino-transferase, although there was no correlation between serum hyaluronan levels and alanine amino-transferase activities.

Conclusion: Serum hyaluronan thus appears to be a non-invasive index of liver fibrosis.

References (20)

There are more references available in the full text version of this article.

Cited by (109)

  • Investigation of Serum Markers of Hepatic Fibrosis in Equids

    2023, Journal of Equine Veterinary Science
  • Modulation of hyaluronan signaling as a therapeutic target in human disease

    2022, Pharmacology and Therapeutics
    Citation Excerpt :

    Dysregulation of HA metabolism is a hallmark of many inflammatory and degenerative diseases. Increased levels of circulating or tissue HA have been found in many lung disorders including asthma, COPD, interstitial lung disease, and pulmonary hypertension (Lauer, Dweik, Garantziotis, & Aronica, 2015; Lennon & Singleton, 2011), as well as inflammatory, fibrotic and degenerative diseases like rheumatoid arthritis (Poole et al., 1990), hepatitis (Guechot et al., 1995; Peters et al., 2013), cirrhosis (Gudowska et al., 2016; Plevris et al., 2000), chronic kidney disease (Stridh, Palm, & Hansell, 2012), atherosclerosis (Fischer, 2019), cardiac remodeling in failure (Hackert et al., 2021), diabetic pancreas (Bogdani et al., 2014), allograft rejection (Cui et al., 2015b; Todd et al., 2014; Wells et al., 1993), virtually every type of solid cancer (Tammi et al., 2008; Toole, 2004; Toole, 2020; Toole et al., 2008), etc. In most, or all these diseases, elevated serum levels of HA have been associated with adverse outcomes and worse prognosis.

  • The liver fibrosis niche: Novel insights into the interplay between fibrosis-composing mesenchymal cells, immune cells, endothelial cells, and extracellular matrix

    2020, Food and Chemical Toxicology
    Citation Excerpt :

    Elastin-derived peptides are bioactive and act as chemoattractants for monocytes, fibroblasts, and endothelial cells (Duca et al., 2004). HA is a major glycosaminoglycan produced and deposited in liver fibrosis, and its serum level has been used as a biomarker for diagnosing the stages of liver fibrosis in clinical practice (Neuman et al., 2016; Tamaki et al., 1996; Guechot et al., 1995), with higher levels indicating poorer prognoses in patients with chronic liver injury (Peters et al., 2013; Hansen et al., 2019; Korner et al., 1996). Large deposits of HA are seen in fibrotic areas of diseased livers, while no or minimal HA deposition is observed in the normal liver (Yang et al., 2019; Satoh et al., 2000).

  • Platelet hyaluronidase-2: An enzyme that translocates to the surface upon activation to function in extracellular matrix degradation

    2015, Blood
    Citation Excerpt :

    This is important because HA is upregulated during inflammation in many tissues, and smooth muscle cells and myofibroblasts are considered to be the major HA-producing cells. High levels of HA deposition have been reported in several inflammatory diseases including asthma, arthritis, and hepatitis.8,9,44,45 In addition, our group has reported an upregulation of HA in the intestines of patients with IBD, a chronic condition characterized by tissue erosion and intestinal bleeding.10,46

  • The chronic enteropathogenic disease schistosomiasis

    2014, International Journal of Infectious Diseases
    Citation Excerpt :

    Hyaluronic acid (HA), a high molecular weight GAG, is an essential ECM component. It is synthesized by HSCs and is degraded by the sinusoidal endothelial cells.78,79 Increased levels are due either to decreased hepatic removal or to increased production by stellate cells, or to both processes.80

  • Serological markers of fibrosis

    2012, Gastroenterologia y Hepatologia
View all citing articles on Scopus
View full text